Follow-up Laboratory Testing for Isolated Thrombocytosis
For a patient with isolated thrombocytosis and otherwise normal CBC, obtain a peripheral blood smear, inflammatory markers (CRP), ferritin, and assess for clinical factors associated with secondary causes before pursuing molecular testing for essential thrombocythemia.
Initial Clinical Assessment
The first step is distinguishing between secondary (reactive) thrombocytosis and essential thrombocythemia (ET), as this fundamentally changes management and prognosis. Secondary thrombocytosis is far more common and carries a benign prognosis, while ET is a myeloproliferative neoplasm requiring long-term monitoring and potential treatment 1.
Key Clinical Factors to Evaluate
Assess for secondary causes systematically:
- Active malignancy – strongly associated with secondary thrombocytosis 1
- Chronic inflammatory disease (inflammatory bowel disease, rheumatoid arthritis, chronic infections) – strongly associated with secondary thrombocytosis 1
- Iron deficiency anemia – even with normal hemoglobin, check ferritin as iron deficiency commonly causes reactive thrombocytosis 1
- History of splenectomy – associated with persistent secondary thrombocytosis 1
- Recent surgery, trauma, or acute infection – common transient causes 1
- History of arterial thrombosis – suggests ET rather than secondary thrombocytosis 1
Essential Laboratory Follow-up Tests
First-Tier Laboratory Studies
Order these tests initially:
- Peripheral blood smear – essential to confirm true thrombocytosis, assess platelet morphology, and exclude other hematologic abnormalities 2, 1
- C-reactive protein (CRP) – elevated in inflammatory conditions causing secondary thrombocytosis 3, 1
- Ferritin – to identify iron deficiency, a common cause of secondary thrombocytosis 1
- Complete metabolic panel – to assess for underlying inflammatory or malignant conditions 3
Laboratory Findings Suggesting Essential Thrombocythemia vs. Secondary Thrombocytosis
ET is more likely when:
- Higher hemoglobin levels 1
- Higher mean corpuscular volume (MCV) 1
- Higher red cell distribution width (RDW) 1
- Higher mean platelet volume (MPV) 1
- History of arterial thrombosis 1
Secondary thrombocytosis is more likely when:
- Higher white blood cell count and neutrophil count 1
- Elevated inflammatory markers 1
- Low ferritin 1
- Presence of clinical factors listed above 1
When to Pursue Molecular Testing
Molecular testing (JAK2, CALR, MPL mutations) should be reserved for patients where:
- Clinical and laboratory evaluation does NOT identify a clear secondary cause 1
- Thrombocytosis is persistent (recheck platelet count after treating any identified secondary causes) 1
- Patient has features suggestive of ET (higher hemoglobin, MCV, RDW, MPV, or history of thrombosis) 1
The overall yield of molecular testing in unselected thrombocytosis patients is only 52.4%, with 92.1% of positive results being JAK2, CALR, or MPL mutations 1. This emphasizes the importance of clinical screening to avoid unnecessary costly testing.
Molecular Testing Panel
If molecular testing is indicated:
- Test for JAK2V617F mutation first, as it is the most common 4, 1
- If JAK2 negative, test for CALR and MPL mutations 4, 1
- These three mutations account for >90% of ET cases with positive molecular findings 1
Common Pitfalls to Avoid
Do not order molecular testing reflexively – the majority of thrombocytosis cases are secondary and do not require expensive genetic testing 1. A systematic clinical and basic laboratory evaluation will identify most secondary causes.
Do not overlook iron deficiency – ferritin should be checked even when hemoglobin is normal, as iron deficiency commonly causes isolated thrombocytosis 1.
Repeat platelet count – ensure thrombocytosis is persistent rather than transient before extensive workup 1.
Consider bone marrow examination only if molecular testing is positive or there are other concerning CBC abnormalities suggesting a myeloproliferative neoplasm 2. Bone marrow is not routinely needed for isolated thrombocytosis evaluation.